Merck announces Grant for Growth Innovation recipients

pharmafield logo - pharma news

Merck has announced the recipients of the Grant for Growth Innovation for 2016. The awards support innovative projects and pioneers of new research for the advancement of science and medical research in the field of growth. 

The winners were announced at an awards presentation organised by Merck during the 55th European Society for Pediatric Endocrinology (ESPE) Meeting in Paris, France.

38 applications from 20 countries were received and reviewed by an independent Scientific Steering Committee composed of five internationally renowned endocrinologists and researchers. Following a rigorous selection process, three awards were offered to innovative projects which seek to advance understanding in the field of growth.

The winning projects are based in Australia, Italy and Brazil. The awards go to:

  • Andrew J. Brooks, University of Queensland Diamantina Institute, Brisbane, Australia 

Project: Targeting the transmembrane domain of the growth hormone receptor to develop new drug classes addressing unmet needs in treatment of growth hormone disorders.

  • Dr Antonio Cittadini, PhD, Federico II University, Naples, Italy 

Project: Treatment of growth hormone deficiency associated with chronic heart failure: A randomised, double-blind, placebo-controlled study.

  • Dr Alexander Augusto de Lima Jorge, PhD, University of São Paulo Medical School, Brazil 

Project: Growth hormone and oestrogen pharmacogenetics in patients with Turner syndrome.

Dr Steven Hildemann, Global Chief Medical Officer and Head of Global Medical and Safety at Merck´s Biopharma business, said: “It is inspiring to see the high quality and aspiration of the researchers to whom these grants have been awarded. We recognise that despite advances in treatment and management of growth disorders, we still require a better understanding of these diseases to address the high unmet medical need. We look forward to seeing the results of these projects.”